Abstract
Background
A lack of drug safety and efficacy studies in pediatric patients is a major problem contributing to inappropriate drug use among this population. The prevalence of ‘off-label’ drug use is high in pediatric patients, leading to an increased risk of adverse events (AEs). A pharmacovigilance database is useful for healthcare providers in monitoring AEs associated with off-label drug use.
Objectives
The aim of this study was to explore the characteristics of AEs reported among pediatric patients aged 1 month to 2 years who received off-label drugs, using information derived from the Thai pharmacovigilance database.
Methods
Spontaneous reports of AEs in pediatric patients aged 1 month to 2 years were derived from the Thai Health Product Vigilance Center (HPVC) database for the period of January 1984 to November 2013. Off-label drug use was defined as drug use outside the age range indicated by US FDA and European Medicines Agency (EMA) drug labeling. Descriptive statistics were used to describe demographics and Anatomical Therapeutic Chemical (ATC) drug classes. Reporting odds ratios were used to evaluate associations between off-label drug use and AE seriousness and the occurrence of critical AEs.
Results
A total of 22,294 AE reports were collected, with 21,390 AE reports meeting the inclusion criteria. These reports were further classified as those involving off-age drug use (5.2 %), age-label drug use (65.2 %), and unclear/unfound age labeling (29.6 %). Of those containing off-age drug use, most were in the ATC anatomical main group of nervous system agents (24.1 %), followed by systemic anti-infective agents (20.5 %). There was a significant association between off-label drug use and the occurrence of critical AEs.
Conclusions
Off-label drug use is associated with unwanted AEs. Therefore, assessing the risk versus benefit of each drug should be taken into consideration before prescribing off-label drugs for pediatric patients.
Similar content being viewed by others
References
Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320(7227):79–82.
Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol. 2003;17(1):125–31.
Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med. 1959;261:1318–21.
Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25(1):1–5.
Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.
Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91(5):796–801.
Ballard CDJ, Peterson GM, Thompson AJ, et al. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health. 2013;49(1):38–42.
Bazzano AT, Mangione-Smith R, Schonlau M, et al. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9(2):81–8.
Carnovale C, Conti V, Perrone V, et al. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172(12):1679–85.
Chalumeau M, Treluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child. 2000;83(6):502–5.
Dell’Aera M, Gasbarro AR, Padovano M, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci. 2007;29(4):361–7.
Lass J, Irs A, Pisarev H, et al. Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf. 2011;20(5):474–81.
Lindell-Osuagwu L, Korhonen MJ, Saano S, et al. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009;34(3):277–87.
McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000;83(6):498–501.
Olsson J, Kimland E, Pettersson S, et al. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care: a nationwide study. Acta Paediatr. 2011;100(9):1272–5.
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.
Phan H, Leder M, Fishley M, et al. Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. Pediatr Emerg Care. 2010;26(6):424–30.
Ribeiro M, Jorge A, Macedo AF. Off-label drug prescribing in a Portuguese paediatric emergency unit. Int J Clin Pharm. 2013;35(1):30–6.
Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111(2):291–5.
Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3):282–90.
Jong GW, van der Linden PD, Bakker EM, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002;58(4):293–7.
Ufer M, Rane A, Karlsson Å, et al. Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol. 2003;58(11):779–83.
Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54(6):665–70.
Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27(13):1059–67.
Zhang L, Li Y, Liu Y, et al. Pediatric off-label drug use in China: risk factors and management strategies. J Evid Based Med. 2013;6(1):4–18.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) 2013 [cited 2015 October 1]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp.
Aagaard L, Hansen EH. Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactions. Br J Clin Pharmacol. 2011;71(5):751–7.
Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PloS One. 2014;9(10):e108970.
Trenque T, Herlem E, Abou Taam M, et al. Methylphenidate off-label use and safety. SpringerPlus. 2014;3:286.
Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–19.
The Thai Food and Drug Administration. Pharmacovigilance in Thailand. In: Health MoP, editor. Bangkok: Thai Food and Drug Administration, Ministry of Public Health; 2008.
Lindquist M. Documentation grading of ICSRS and improved data quality management in Vigibase [abstract no. P.060]. Drug Saf. 2007;30(10):1002.
WHO Collaboration Centre for Drug Statistics Methodology. WHOCC—ATC/DDD 2015 [cited 2015 October 1].
Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004;13(3):147–52.
Jonville-Bera AP, Bera F, Autret-Leca E. Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. Eur J Clin Pharmacol. 2005;61(3):231–6.
Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;88(9):965–8.
Acknowledgments
The authors would especially like to acknowledge and thank the Health Product Vigilance Center (HPVC), Food and Drug Administration, Ministry of Public Health, Thailand, for data permission. We would also like to thank Assoc. Prof. Dr. Michael Oszko, Lawrence Memorial Hospital, Kansas, USA, for his support in manuscript writing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used in conducting this research or preparing this manuscript.
Conflict of interest
The authors declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Niamtaworn, P., Suwankesawong, W., Subongkot, S. et al. Off-label use and pharmacovigilance among infants: analysis of the Thai Health Product Vigilance National Database. Drugs Ther Perspect 32, 304–310 (2016). https://doi.org/10.1007/s40267-016-0300-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-016-0300-y